U.S. Life Sciences Stock News

Murphy Oil, NYSE:MUR, reported two consecutive dry wells in its offshore Côte d'Ivoire exploration campaign. The company is abandoning the Caracal-1X well after non commercial results. Despite these outcomes, Murphy Oil plans to proceed with drilling a third well, Bubale-1X, in a different geological structure. For investors tracking NYSE:MUR, this update comes with the stock at $33.15 and a 1 year return of 31.6%, alongside a 5 year return of 95.6%. At the same time, the stock shows mixed...

Vistra (VST) has wrapped up FY 2025 with Q4 revenue of US$4.6b, Basic EPS of US$0.55, and net income of US$185m, while trailing twelve month figures show revenue of US$17.7b and Basic EPS of US$2.23 anchored by net income of US$752m. The company has seen quarterly revenue range from US$3.9b to US$5.0b across 2025, with Basic EPS swinging from a Q1 loss of US$0.93 to a Q3 figure of US$1.78. This sets up a results picture where investors are likely to focus on how those earnings translate into...

Primo Brands (PRMB) closed FY 2025 with Q4 revenue of US$1.6b and basic EPS of a US$0.07 loss, capping off a trailing twelve month period where revenue reached US$6.7b and EPS came in at US$0.22. Over recent quarters, the company has seen revenue range from US$1.4b in Q4 FY 2024 to US$1.8b in Q3 FY 2025, while quarterly EPS moved between a US$0.49 loss and US$0.24. This set the scene for a year that turned profitable on a trailing basis despite a softer fourth quarter. For investors, the mix...

Ambarella (AMBA) has just closed out FY 2026 with fourth quarter revenue of US$100.9 million and a basic EPS loss of US$0.38, set against trailing twelve month revenue of US$390.7 million and a TTM EPS loss of US$1.78. Over the past six reported quarters, the company has seen quarterly revenue range from US$82.7 million to US$108.5 million while basic EPS losses have moved between US$0.35 and US$0.58. This gives investors a clear view of how growth ambitions are currently weighing on the...

Global Industrial Company recently reported fourth-quarter 2025 sales of US$345.6 million and net income of US$14.6 million, alongside full-year 2025 sales of US$1.38 billion and net income of US$72.1 million, and raised its quarterly dividend by 7.7% to US$0.28 per share. The combination of higher sales, improved earnings per share, an eleventh consecutive annual dividend increase, and ongoing share repurchases highlights management’s focus on cash generation and shareholder returns while...

Wondering if Montrose Environmental Group at around US$29.22 is offering fair value today, or if the recent excitement has already been priced in? The stock has logged returns of 26.5% over the last 7 days, 30.2% over the last 30 days, 17.4% year to date and 50.4% over the last year, while the 3 year and 5 year returns sit at 21.4% and 28.6% declines. This price action comes as investors continue to assess Montrose Environmental Group's position in environmental services and its execution on...

If you are wondering whether Empire State Realty Trust's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are actually saying about value. The stock last closed at US$5.88, with returns of 0.8% decline over 7 days, 9.8% decline over 30 days, 9.1% decline year to date and 35.4% decline over 1 year. This naturally raises questions about whether the market is reassessing its risks or overlooking potential. Recent coverage around...

If you are looking at Natural Resource Partners and wondering whether the current price reflects its true value, this article will walk you through what the numbers are really saying. The stock closed at US$121.05, with returns of a 1.8% decline over 7 days, 6.0% over 30 days, 16.4% year to date, 19.6% over 1 year and a very large gain over 5 years. This naturally raises questions about how the current price stacks up against fundamentals. Recent interest in Natural Resource Partners has...

Figure Technology Solutions (FIGR) FY 2025 Earnings Snapshot Figure Technology Solutions (FIGR) has capped FY 2025 with Q4 revenue of US$135.6 million and basic EPS of US$0.07, alongside trailing twelve month revenue of US$432.1 million and EPS of US$1.17 that put the latest figures into a fuller context. The company has seen quarterly revenue move from US$67.9 million in Q1 2025 to US$90.0 million in Q2, US$138.5 million in Q3 and US$135.6 million in Q4, while basic EPS has ranged from a...

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...

Burlington Stores (NYSE:BURL) plans to open 110 net new stores in 2026, ahead of earlier expectations. The company is also expanding its corporate office footprint in New York to support a larger organization. These moves reflect management's intent to scale operations and reinforce Burlington's long term growth plans. Burlington Stores comes into this announcement with its shares at $306.62 and a 1 year return of 23.0%. Over 3 years the stock has returned 41.8%, and over 5 years 9.8%,...

AbCellera Biologics Inc. has reported its full-year 2025 results, with revenue rising to US$75.13 million and net loss easing to US$146.41 million, while also filing a US$45.54 million shelf registration for 15,030,034 common shares tied to an employee share offering. Alongside these financials, AbCellera’s shift into a clinical-stage biotech with advancing programs ABCL635 and ABCL575 and a nearly completed manufacturing facility signals a business model increasingly centered on internal...

Arlo Technologies (ARLO) closed out FY 2025 with Q4 revenue of US$141.3 million and basic EPS of US$0.05, alongside net income of US$5.8 million. The trailing 12 month line shows revenue of US$529.3 million and basic EPS of US$0.14 as the business moves further into consistent profitability. Over the past six quarters, the company has seen revenue range from US$119.1 million to US$141.3 million per quarter, with basic EPS shifting from a loss of US$0.05 in late 2024 to positive contributions...

Helix Energy Solutions Group (HLX) is back in focus after reporting its highest fourth quarter revenue since 2013, positive free cash flow, and year end cash and liquidity that support recently secured multiyear contracts. See our latest analysis for Helix Energy Solutions Group. Those results come after a busy period, with Helix Energy Solutions Group reporting full year 2025 earnings, recording a US$18.06 million long lived asset impairment, completing its share repurchase program, and...

If you are wondering whether Oddity Tech is now a bargain or a value trap, a closer look at how its current share price lines up with its fundamentals can help frame that question. The stock has seen large price swings recently, with a 7 day return of 63.2% decline, a 30 day return of 64.8% decline, and a year to date return of 70.2% decline, while the 1 year return sits at 75.3% decline from the current last close of US$11.77. These moves have prompted renewed attention on the business, as...

Centuri Holdings (NYSE:CTRI) reported record revenue and profitability for 2025. The company secured a 59% increase in backlog to $5.9b, supporting 2026 revenue visibility. Centuri announced expansion into new states and maintained a 100% Master Service Agreement renewal rate. Management is adjusting fleet funding and working to reduce seasonality in its gas business. Centuri Holdings enters 2026 with fresh momentum, backed by record 2025 financial results and a growing project book. The...

OneStream (OS) just closed out FY 2025 with Q4 revenue of US$163.7 million, Basic EPS of US$0.01, and net income of US$1.0 million, set against trailing 12 month revenue of US$601.9 million and a loss of US$50.3 million. The company has seen quarterly revenue move from US$132.5 million in Q4 FY 2024 to US$163.7 million in Q4 FY 2025, while Basic EPS shifted from a loss of US$0.10 to a slight profit of US$0.01 over the same period. This frames a story where top line growth is occurring...

BridgeBio Pharma (NasdaqGS:BBIO) released positive top line Phase 3 data for Encaleret, BBP-418 and Infigratinib. The company reported strong commercial momentum for its product Attruby, supporting a move toward cash generation. Management framed this combination of clinical and commercial news as a pivotal inflection in the business model. BridgeBio Pharma comes into this update with a current share price of $66.445 and a very large 3 year return, alongside a 90.4% return over the past...

Fortrea Holdings (NasdaqGS:FTRE) has reshaped its executive ranks, naming Scott Dove, PhD, as President of Clinical Pharmacology Services. Oren Cohen, MD, is shifting into a more focused position as Chief Medical Officer, concentrating on Fortrea's medical direction. These changes highlight management's attention on clinical research and development within the broader contract research space. For investors watching Fortrea at a share price of $10.71, the company is pairing leadership moves...